Secondary endpoint results for immunogenicity
The incidence of treatment-emergent anti-gosuranemab antibody responses was low at all time points and similar between all gosuranemab dose groups and the placebo group. One participant in the intermediate-dose group (1.0%) and four participants in the placebo group (1.9%) had a positive treatment-emergent anti-gosuranemab antibody response at any time point after baseline and within the week 76 visit. Persistent responses were observed in two participants in the placebo group (0.9%); no participants in the gosuranemab-treated groups showed a persistent response. Transient responses were observed in two participants in the placebo group (0.9%) and one participant in the intermediate-dose group (1.0%).